Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 0373 • ACR Convergence 2025
Implementation of a Lupus Self-Management mHealth App: Using Incentives to Drive Engagement
Melissa French¹, Katherine Carpenter², Eric Johnson², Melicent Miller² and Mary Crimmings², ¹Lupus Foundation of America, Alexandria, VA, ²Lupus Foundation of America, Washington, DC
Background/Purpose: As part of a five-year cooperative agreement with the Centers for Disease Control and Prevention, the Lupus Foundation of America (LFA) has implemented the…
Abstract Number: 0126 • ACR Convergence 2025
Performance of the 2023 and 2006 APS Classification Criteria in Pediatric Patients Diagnosed with APS: A Multisite Cohort Study
Jacqueline Madison¹, Elizabeth Sloan², Cristina Saez³, Olivia Kwan⁴, Kevin Lewis¹, Jonathan Marilao⁵, Blake Baay⁶, Rasha Elrefai⁴, Marissa Dale⁷, Deborah McCurdy⁸, Jheel Bhatt⁹, Sasidhar Goteti¹⁰, Ekemini Ogbu¹¹, Jason S. Knight¹ and Yu (Ray) Zuo¹, ¹University of Michigan, Ann Arbor, MI, ²UT Southwestern, Children's Medical Center, and Scottish Rite for Children, Dallas, TX, ³Children's Hospital Colorado, Glendale, CO, ⁴Baylor College of Medicine, Houston, TX, ⁵University of Texas Southwestern, Dallas, TX, ⁶Scottish Rite for Children, Dallas, TX, ⁷Hospital for Special Surgery/NYP Cornell, New York, NY, ⁸UCLA Medical Center, Los Angeles, CA, ⁹Advent Health Orlando, Orlando, FL, ¹⁰University of Utah, Salt Lake City, UT, ¹¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Antiphospholipid syndrome (APS) is a thrombo-inflammatory disorder that causes significant morbidity and mortality, even in children. The 2023 ACR/EULAR classification criteria, which use weighted…
Abstract Number: 2646 • ACR Convergence 2025
DNA methylation-based clustering reveals clinically distinct subtypes of systemic lupus erythematosus
Meghan Nelson¹, Mary Horton², Joanne Nititham², Jinoos Yazdany³, Maria Dall'Era⁴, Cristina Lanata⁵ and Lindsey Criswell², ¹NIH/NIAMS/NHGRI, Bethesda, MD, ²NIH/NHGRI, Bethesda, MD, ³UCSF, San Francisco, CA, ⁴Division of Rheumatology, University of California, San Francisco, CA, ⁵NIH/NHGRI, Bethesda
Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogenous autoimmune disease with significant variability in clinical presentation. DNA methylation has been associated with lupus risk and…
Abstract Number: 2561 • ACR Convergence 2025
Patient-Centricity: The Keystone to Recruitment and Retention of Research Participants for the Lupus Landmark Study and the Success of the Lupus Nexus
Mary Jo Fekete¹, Amonte Davis¹, Courtney Canton², Caroline Donovan³, Carla Menezes⁴, Derek Bennett⁵, Brianna Fitzpatrick⁵, Jamila Jones⁵, Alison Lee⁵, Martin Lewis⁵, Lillian Mendez⁶, Christine Perkins⁷, Dayani Tipple⁸, Ruth Wilson⁹, S. Sam Lim¹⁰, Arezou Khosroshahi¹¹, Alfred Kim¹² and Devon Kelly¹³, ¹Lupus Research Alliance, New York, ²Lupus Therapeutics, Charleston, SC, ³Lupus Therapeutics, Charlottesville, VA, ⁴Lupus Therapeutics, New York, NY, ⁵Patient Advocate, New York, ⁶Patient Advocate, Carteret, NJ, ⁷Patient Advocate, Seattle, Washington, ⁸AstraZeneca, Wilmington, DE, ⁹Patient Advocate, Auburn, IN, ¹⁰Emory University School of Medicine, Atlanta, GA, ¹¹Emory University, Atlanta, GA, ¹²Washington University School of Medicine, St. Louis, MO, ¹³Lupus Research Alliance, New York, NY
Background/Purpose: Community-wide access to highly curated, extensive datasets is critical to advance disease understanding and accelerate precision medicine. To address this unmet need in lupus,…
Abstract Number: 2457 • ACR Convergence 2025
Maternal, Embryo-Fetal And Neonatal Outcomes Following Belimumab Exposure During Pregnancy In Patients With Systemic Lupus Erythematosus
Kenza El Ouazzani¹, Nathalie Morel¹, Delphine Beghin², Gaelle GUETTROT-IMBERT³, Noémie JOURDE-CHICHE⁴, Alban DEROUX⁵, Françoise Sarrot-Reynauld⁵, Lionel Couzi¹, Vincent Langlois⁶, Estibaliz LAZARO⁷, Pauline ORQUEVAUX⁸, Benjamin DE SAINTE MARIE⁹, Kevin Deve¹⁰, christophe Deligny¹¹, Nicole Ferreira¹², Bertrand Godeau¹³, Véronique Le Guern³, Raphaelle Meunier¹⁴, Elisabeth Pasquier¹⁵, Viviane Queyrel Moranne¹⁶, Laurent Sailler¹⁷, Cécile Saint-Pastou¹⁸, Nathalie Costedoat-Chalumeau³, Benoit Marin¹⁹ and Christophe Richez¹, ¹Bordeaux University Hospital, Bordeaux, France, ²Paris Pitié-Salpêtrière Hospital, Paris, France, ³Cochin Hospital, Paris, France, ⁴Centre de Néphrologie et Transplantation Rénale, Hôpital de la Conception, Assistance Publique-Hôpitaux de Marseille, Marseille, France., Marseille, France, ⁵Grenoble university hospital, Grenoble, France, ⁶Le Havre University Hospital, Le Havre, France, ⁷Bordeaux University Hospital, Pessac, France, ⁸Reims University Hospital, Reims, France, ⁹Timone university hospital, Marseille, France, ¹⁰Bayonne hospital, Bayonne, France, ¹¹Fort-de-France hospital, Fort-de-France, France, ¹²Tours University Hospital, Tours, France, ¹³Creteil Hospital, Paris, France, ¹⁴Libourne Hospital, Libourne, France, ¹⁵Brest University Hospital, Brest, France, ¹⁶Nice University Hospital, Nice, France, ¹⁷CHU Toulouse, Toulouse, France, ¹⁸Saint-Pierre Hospital, Saint-Pierre, France, ¹⁹Hôpital Pitié-Salpêtrière, Paris, France
Background/Purpose: Systemic lupus erythematosus (SLE) may be associated with high-risk pregnancies, especially in the presence of specific predisposing factors. While optimal disease control during pregnancy…
Abstract Number: 2439 • ACR Convergence 2025
Belimumab Versus Mycophenolate Mofetil in Lupus Nephritis: A Real-World Comparative Analysis
Ahmad Alomari¹, Nikita Shah², Miguel Rodriguez³ and Diala Alawneh⁴, ¹UCF- North Florida hospital, Gainesville, FL, ²UCF/HCA Florida North Florida Hospital, Gainesville, FL, ³SIMED Rheumatology, Gainesville, FL, ⁴University of Florida, Gainesville, FL
Background/Purpose: Lupus nephritis (LN) is a serious complication of systemic lupus erythematosus (SLE), often leading to chronic kidney disease (CKD) and end-stage renal disease (ESRD).…
Abstract Number: 2420 • ACR Convergence 2025
In-patient Outcomes of Diabetic Ketoacidosis and Hyperglycemic Hyperosmolar Syndrome in SLE: US National Inpatient Database (2021-2022)
Nattanicha Chaisrimaneepan¹, Pitchaporn Yingchoncharoen² and Miriam Paz², ¹Department of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, ²Texas Tech University Health Sciences Center, Lubbock
Background/Purpose: Systemic lupus erythematosus (SLE is an autoimmune disease that attacks different organs. There have been reports of hyperglycemic hyperosmolar syndrome (HHS) from steroid use…
Abstract Number: 2403 • ACR Convergence 2025
Differential Risk of Inpatient Admissions Among SLE Subgroups: A Population-Based Analysis
Jaime Flores-Gouyonnet¹, Erika Navarro-Mendoza¹, Mario Bautista-Vargas¹, Ali Ardekani¹, Maria Cuellar-Gutierrez¹, Gabriel Figueroa-Parra², Mariana Gonzalez-Treviño³, Alain Sanchez-Rodriguez⁴, Andrew C. Hanson¹, Cassondra Hulshizer⁵, Cynthia Crowson⁶ and Ali Duarte-Garcia¹, ¹Mayo Clinic, Rochester, MN, ²Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico, ³Vanderbilt University Medical Center, Nashville, TN, ⁴ABC Medical Center, Ciudad de México, Federal District, Mexico, ⁵Mayo Clinic, Rochester, ⁶Mayo Clinic, Stewartvillle, MN
Background/Purpose: SLE is clinically heterogeneous and associated with increased hospitalizations. However, it remains unclear which patient subgroups drive this excess in unplanned healthcare use. We…
Abstract Number: 2385 • ACR Convergence 2025
The Presence of Avascular Necrosis in Patients with Systemic Lupus Erythematosus Undergoing Total Knee Arthroplasty is Not Associated with Worse Outcomes
Billy Kim¹, Ahmed Deeb¹, Douglas Mintz¹, Susan Goodman², Jose Rodriguez², Mark Figgie² and Jason Blevins³, ¹Hospital for Special Surgery, New York, ²Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ³Hospital for Special Surgery, New York, NY
Background/Purpose: Systemic lupus erythematosus (SLE) patients seeking total knee arthroplasty (TKA) may present with secondary avascular necrosis (AVN) of the knee due to high-dose glucocorticoid…
Abstract Number: 2220 • ACR Convergence 2025
Human Milk Fatty Acid Profiles Among Breastfeeding Mothers With and Without Systemic Autoimmune Rheumatic Diseases
Rashmi Dhital¹, Kerri Bertrand², Dilli Poudel³, Christina Chambers⁴ and Monica Guma², ¹Vanderbilt University Medical Center, Brentwood, TN, ²University of California San Diego, San Diego, CA, ³Vanderbilt University Medical Center, Nashville, TN, ⁴University of California, San Diego, La Jolla, CA
Background/Purpose: Systemic autoimmune rheumatic diseases (SARDs) such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) are characterized by chronic systemic inflammation and often require…
Abstract Number: 1989 • ACR Convergence 2025
Moving Out of the Kid’s Rheum: Transitioning Young Adult Patients from Pediatric to Adult Rheumatology Practices
Victoria Koenigsberger¹, Madeleine Ward², Meghan Geary³ and Ali Yalcindag⁴, ¹The Warren Alpert Medical School of Brown University, Providence, RI, ²The Warren Alpert Medical School of Brown University, Division of Medicine-Pediatrics, Providence, ³The Warren Alpert Medical School of Brown University, Division of General Internal Medicine, Providence, ⁴The Warren Alpert Medical School of Brown University, Division of Rheumatology, Department of Pediatrics, Milton, MA
Background/Purpose: Young adults with childhood-onset rheumatic conditions encounter challenges and barriers to care when transitioning to an adult rheumatologist. At this Pediatric Rheumatology Clinic, patients…
Abstract Number: 1878 • ACR Convergence 2025
Customized Therapy for SLE: How Disease Severity Influences the Use of Corticosteroids and Biologics in Patients with SLE in the Lupus Federated Data Network (LupusNet) and a US Claims Database
Ashley Orillion¹, Federico Zazzetti², Anna Sheahan³, Clair Blacketer¹, Michel van Speybroeck⁴, Sarah Gasman¹, Reyhan Sonmez⁵, Erika Noss¹, Manuel Ugarte-Gil⁶, Rocío Gamboa-Cárdenas⁷, Víctor Pimentel-Quiroz⁸, Kaleb Michaud⁹, Patti Katz¹⁰, Rangi Kandane-Rathnayake¹¹, Eric Morand¹², Worawit Louthrenoo¹³, Alberta Hoi¹⁴, Yi-Hsing Chen¹⁵, Jiacai Cho¹⁶, Laniyati Hamijoyo¹⁷, Shue Fen Luo¹⁸, Sandra Navarra¹⁹, Mandana Nikpour²⁰, José María Pego-Reigosa²¹, Iñigo Rúa-Figueroa²², Zulema Plaza²³, María Galindo-Izquierdo²⁴, Julia Martínez Barrio²⁵, Jaime Calvo²⁶, Antonio Fernández-Nebro²⁷, Raúl Menor Almagro²⁸, EVA GLORIA TOMERO MURIEL²⁹, Javier Narváez³⁰ and Chetan S. Karyekar³¹, ¹Johnson & Johnson, Spring House, PA, USA, Spring House, PA, ²Johnson & Johnson, Horsham, PA, USA, Ambler, PA, ³Johnson & Johnson, Horsham, PA, USA, Horhsam, PA, ⁴Johnson & Johnson, Beerse, Belgium, Beerse, Belgium, ⁵Capgemini Consulting, Zurich, Switzerland, Zurich, Switzerland, ⁶Grupo Peruano de Estudio de Enfermedades Autoinmunes Sistémicas, Universidad Científica del Sur, Lima, Peru; Hospital Guillermo Almenara Irigoyen, EsSalud, Lima, Peru, Lima, Peru, ⁷Universidad Científica del Sur, Lima, Peru, ⁸Grupo Peruano de Estudio de Enfermedades Autoinmunes Sistémicas, Universidad Científica del Sur, Lima, Perú; Rheumatology Department, Hospital Guillermo Almenara Irigoyen, EsSalud, Lima, Perú, Lima, Peru, ⁹University of Nebraska Medical Center, Omaha, NE, ¹⁰UCSF, San Rafael, CA, ¹¹Center for Inflammatory Diseases, Monash University, Clayton, Victoria, Australia, ¹²Centre for Inflammatory Diseases, Monash University and Monash Health, Melbourne, Victoria, Australia, ¹³Chiang Mai University Hospital, Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai, Thailand, Chiang Mai, Thailand, ¹⁴Centre for Inflammatory Diseases, Monash University and Department of Rheumatology, Monash Health, Clayton, Victoria, Australia, ¹⁵Taichung Veterans General Hospital, Division of Allergy, Immunology and Rheumatology, Taichung, Taiwan, Taichung, Taiwan (Republic of China), ¹⁶National University Hospital, Rheumatology Division, Department of Medicine, Singapore, Singapore, Singapore, Singapore, ¹⁷Padjadjaran University/Hasan Sadikin General Hospital, Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Bandung, Indonesia, Badung, Indonesia, ¹⁸Chang Gung Memorial Hospital, Chang Gung University, Department of Rheumatology, Allergy and Immunology, Taipei, Taiwan, Taoyuan, Taiwan (Republic of China), ¹⁹University of Santo Tomas, Manila, Philippines, ²⁰University of Sydney, School of Public Health, Faculty of Medicine and Health, Sydney, New South Wales, Australia; St Vincent’s Hospital Melbourne, Department of Rheumatology, Fitzroy, Victoria, Australia, Melbourne, Victoria, Australia, ²¹Department of Rheumatology, University Hospital of Vigo, Vigo, Spain; IRIDIS Group (Investigation in Rheumatology and Immune-Diseases), Galicia Sur Health Research Institute, Vigo, Spain, ²²Hospital de Gran Canaria Doctor Negrin, Las Palmas GC, Spain, ²³Research Unit, Spanish Society of Rheumatology, Madrid, Spain, Madrid, Spain, ²⁴Department of Rheumatology, Hospital Universitario ¹² de Octubre, Madrid, Spain, Madrid, Madrid, Spain, ²⁵Department of Rheumatology, Hospital Gregorio Marañón, Madrid, Spain, Madrid, Madrid, Spain, ²⁶Department of Rheumatology, Hospital Universitario Araba, School of Medicne, Universidad del País Vasco, BIOARABA Health Research Institute, Vitoria, Spain, Vitoria, Pais Vasco, Spain, ²⁷Hospital Regional Universitario de Malaga, Malaga, Spain, Malaga, Spain, ²⁸Department of Rheumatology, Hospital de Jerez, Spain, Puerto De Santa María, Spain, ²⁹Hospital Universitario de la Princesa, Madrid, Spain, ³⁰Hospital Universitario de Bellvitge, Barcelona, Spain, ³¹Johnson & Johnson, Spring House, PA, USA, Spring House
Background/Purpose: The management of SLE varies worldwide. Current SLE treatment goals focus on preventing flares, controlling disease activity, and preventing organ damage accrual. LupusNet is…
Abstract Number: 1837 • ACR Convergence 2025
Enhanced Mitochondrial Activity in B cells from Females Is Required to Drive Increased T-bet Induction by TLR7 in Lupus
John D. Mountz¹, Kathryn Sullivan², Shanrun Liu², Cynthia Liu², Min Gao², Walter Winn Chatham³, Tanecia Mitchell² and Hui-Chen Hsu², ¹University Alabama Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³University of Nevada, Las Vegas, Las Vegas, NV
Background/Purpose: Systemic lupus erythematosus (SLE) is a predominantly female autoimmune disease, with a 9:1 female-to-male ratio. Our previous studies indicated that increased T-bet+ age-related B…
Abstract Number: 1743 • ACR Convergence 2025
Comparative assessment of cardiovascular risk and its predictors in a large cohort of young adults with juvenile systemic lupus erythematosus and juvenile dermatomyositis
Jiangning Li, Shreya Doddi, Tharuni Mailoo and Coziana Ciurtin, University College London, London, United Kingdom
Background/Purpose: Juvenile systemic lupus erythematosus (JSLE) and juvenile dermatomyositis (JDM) are associated with chronic inflammation that can accelerate atherosclerosis. There is no specific guidance regarding…
Abstract Number: 1690 • ACR Convergence 2025
Environmental Heat Exposure and Risk of Systemic Lupus Erythematosus
Jennifer Woo¹, Kaitlyn Lawrence² and Dale Sandler¹, ¹National Institute of Environmental Health Sciences, Durham, NC, ²DLH, Corp., Durham, NC
Background/Purpose: Environmental heat exposures have been linked to increased morbidity and mortality. Individuals with systemic lupus erythematous (SLE) often have heat- and photo- sensitivity, which…

« Previous Page
1
…
5
6
7
8
9
…
181
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].